fbpx

Listen to a Replay of the Q2 2021 Results Conference Call

Delivering More For Patients

POSITIVELY IMPACTING HEALTHCARE

We are committed to developing breakthrough treatments that provide improved safety, efficacy, and convenience for adult and pediatric patients battling cancer.  

Seeing New Possibilities

A MULTI-DISCIPLINARY APPROACH TO CNS TUMORS

Our proprietary platform integrates advances in nanoscale drug delivery, neurosurgery, nuclear medicine, and radiation oncology.

Standing Up To Brain Cancer

DEFYING ODDS ONE PATIENT AT A TIME

Our transformative approach to targeting and eliminating recurrent tumors locally and precisely while reducing side effects systemically means more time in the sun.

Delivering More For Patients

POSITIVELY IMPACTING HEALTHCARE

We are committed to developing breakthrough treatments that provide improved safety, efficacy, and convenience for adult and pediatric patients battling cancer.  

Seeing New Possibilities

A MULTI-DISCIPLINARY APPROACH TO CNS TUMORS

Our proprietary platform integrates advances in nanoscale drug delivery, neurosurgery, nuclear medicine, and radiation oncology.

Standing Up To Brain Cancer

DEFYING ODDS ONE PATIENT AT A TIME

Our transformative approach to targeting and eliminating recurrent tumors locally and precisely while reducing side effects systemically means more time in the sun.

Delivering More For Patients

POSITIVELY IMPACTING HEALTHCARE

We are committed to developing breakthrough treatments that provide improved safety, efficacy, and convenience for adult and pediatric patients battling cancer.  

Seeing New Possibilities

A MULTI-DISCIPLINARY APPROACH TO CNS TUMORS

Our proprietary platform integrates advances in nanoscale drug delivery, neurosurgery, nuclear medicine, and radiation oncology.

Standing Up To Brain Cancer

DEFYING ODDS ONE PATIENT AT A TIME

Our transformative approach to targeting and eliminating recurrent tumors locally and precisely while reducing side effects systemically means more time in the sun.

Developing Innovative, Targeted Radiotherapeutics For Rare & Difficult-To-Treat Cancers

Plus Therapeutics, Inc. is investigating a novel radiotherapeutic, Rhenium-186 NanoLiposome (186RNL), in the U.S. National Institutes of Health-supported ReSPECT™ clinical trial for patients with recurrent glioblastoma – a rare, incurable, and fatal disease.

 

186RNL is designed to emit a Beta Ray to kill tumor cells while sparing surrounding healthy tissues and a Gamma Ray to visualize the therapy during and after administration to the patient.

 

Together, these 2 Rays may help healthcare providers take on this challenging type of brain cancer and give patients Hope.

Watch the Experts

Marc H. Hedrick, MD

Plus Therapeutics President & CEO

Inspiration for the company’s focus on helping patients with glioblastoma live longer.

Michael G. DeCuypere, MD PhD FAANS

Northwestern University Feinberg School of Medicine

A clinical trial plan for treating pediatric brain & spinal cord tumors with a poor prognosis.

Upcoming Events

Investor

September 13-15, Virtual

H.C. Wainwright 23rd Annual Global Investment Conference

Medical & Scientific

October 24-27, Chicago

American Society for Radiation Oncology (ASTRO) Annual Meeting

November 18-21, Boston

Society for Neuro-Oncology (SNO) Annual Meeting

Latest News